FDA warning letters rise 78% over six years with increase expected in 2015

25 September 2014

The number of warning letters sent by the US Food and Drug Administration increased substantially by 78% from 2007 to 2013, with pharma and biotech companies accounting for one of the highest number of warning letters.

Research from Sparta Systems analyzed FDA warning letter trends since 2007. It found that the average growth rate for warning letters issued between 2007 and 2012 was 15.8% per year. The issuing of FDA warning letters increased 78% from 2007 to 2013, even with a 12.4% decrease from 2012 to 2014.

It speculated that the decrease between 2012 and June 30 this year was due to fewer FDA inspections as a result of reduced funding for the FDA and an industry-wide freeze on manufacturers’ FDA fees.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical